European Urology Oncology

European Urology Oncology is a peer-reviewed open access journal published by Elsevier on behalf of the European Association of Urology since 2018 under the eISSN 2588-9311, covering urological cancers including prostate, bladder, kidney and testicular malignancies, with a 2025 Journal Impact Factor of 8.5 and first quartile ranks of 40 of 333 in oncology and 8 of 134 in urology and nephrology《欧洲泌尿肿瘤学》（European Urology Oncology）是欧洲泌尿学会（EAU）主办、爱思唯尔自 2018 年起出版的同行评审开放获取期刊，电子刊号 2588-9311，覆盖前列腺癌、膀胱癌、肾癌与睾丸癌等泌尿系统肿瘤，2025 年影响因子为 8.5，在肿瘤学类 333 种期刊中列第 40 位、在泌尿与肾病学类 134 种期刊中列第 8 位，均居第一四分位。

Scope

• The journal is the official oncology title of the European Association of Urology and publishes original research, reviews, systematic reviews, guidelines and editorials on urological malignancies across the full patient pathway from screening and diagnosis to treatment and survivorship该刊是欧洲泌尿学会（EAU）的肿瘤学官方期刊，刊载泌尿系统恶性肿瘤的原创研究、综述、系统综述、指南与社论，覆盖从筛查、诊断到治疗与随访的全病程。
• It covers prostate cancer including localised and advanced disease, bladder cancer including non-muscle-invasive and muscle-invasive disease, kidney cancer including renal cell carcinoma, testicular cancer and penile cancer, together with less common urological malignancies该刊覆盖前列腺癌（含局限性与进展期）、膀胱癌（含非肌层浸润与肌层浸润）、肾癌（含肾细胞癌）、睾丸癌与阴茎癌，以及较少见的泌尿系统恶性肿瘤。
• The journal addresses translational and clinical research on biomarkers, imaging, surgical techniques including robot-assisted approaches, systemic therapies including immunotherapy and targeted agents, and combination treatment strategies for urological cancers该刊涉及泌尿肿瘤生物标志物、影像、外科技术（含机器人辅助）、系统治疗（含免疫治疗与靶向药物）及联合治疗策略的转化与临床研究。
• As an open access journal it applies a Creative Commons licence to accepted articles and levies an article processing charge on the corresponding author, with waivers available for qualifying authors, and it operates single-blind peer review作为开放获取期刊，该刊对录用文章采用知识共享许可，向通讯作者收取文章处理费，并对符合条件的作者提供减免，实行单盲同行评审。
• The journal is abstracted and indexed in Science Citation Index Expanded, Scopus, PubMed, MEDLINE and Embase, and it is included in the Journal Citation Reports from the Science Citation Index Expanded edition该刊被（SCIE）、（Scopus）、（PubMed）、（MEDLINE）与（Embase）收录，并纳入（SCIE）版期刊引证报告。
• In the 2025 Journal Citation Reports it ranks 40 of 333 titles in oncology with an 88.1 percentile and 8 of 134 titles in urology and nephrology with a 94.4 percentile, with five year indicators in the first quartile for both categories在 2025 年版期刊引证报告中，该刊在肿瘤学类 333 种期刊中列第 40 位、百分位 88.1，在泌尿与肾病学类 134 种期刊中列第 8 位、百分位 94.4，两类五年指标均居第一四分位。

History

• The journal was launched in 2018 as a sister title to European Urology, the flagship journal of the European Association of Urology, to provide a dedicated open access venue for urological oncology research该刊于 2018 年作为欧洲泌尿学会旗舰刊《欧洲泌尿学》（European Urology）的姊妹刊创刊，为泌尿肿瘤学研究提供专门的开放获取平台。
• It has been published as a fully open access title since its first volume, distinguishing it from the hybrid model of the parent European Urology journal and aligning with funder open access mandates该刊自第一卷起即为完全开放获取期刊，区别于母刊《欧洲泌尿学》的混合模式，契合资助机构的开放获取要求。
• The Journal Impact Factor moved from 7.479 in 2021 to 8.208 in 2022, then to 9.3 in 2024 and to 8.5 in 2025, maintaining first quartile standing in both oncology and urology and nephrology throughout该刊影响因子由 2021 年的 7.479 升至 2022 年的 8.208，再升至 2024 年的 9.3 与 2025 年的 8.5，始终居肿瘤学类与泌尿与肾病学类第一四分位。
• The journal has progressively expanded its content to include guideline summaries, trial protocols and consensus statements from European Association of Urology working groups on urological cancers该刊逐步扩展内容，纳入欧洲泌尿学会（EAU）泌尿肿瘤工作组制订的指南摘要、试验方案与共识声明。
• The publisher carries the journal on ScienceDirect and the digital object identifier prefix of its articles is 10.1016, shared with other Elsevier urology titles出版方将该刊载于（ScienceDirect），其文章的数字对象唯一标识符前缀为（10.1016），与爱思唯尔其他泌尿学期刊一致。

Editors

• The journal is led by an editor-in-chief supported by an editorial board whose members are drawn from urological oncology departments, cancer centres and research institutes across Europe and beyond该刊由一位主编带领，配以由欧洲及以外多所泌尿肿瘤科室、癌症中心与研究机构学者组成的编委会。
• The editorial team includes associate editors and section editors responsible for subject areas such as prostate cancer, bladder cancer, kidney cancer, testicular cancer and translational urological oncology, reflecting the breadth of the specialty编辑团队设有副编辑与学科编辑，分别负责前列腺癌、膀胱癌、肾癌、睾丸癌与转化泌尿肿瘤学等方向，对应学科的广度。
• Editorial handling follows the Elsevier editorial management system, with submissions assigned to handling editors based on subject expertise and competing interest declarations稿件处理依托爱思唯尔的编辑管理系统，依据学科专长与利益冲突声明分配责任编辑。
• Peer review is single-blind and the journal maintains the European Association of Urology and Elsevier standards on reviewer recruitment, conflict of interest management, data sharing and editorial independence同行评审采用单盲方式，该刊遵循欧洲泌尿学会（EAU）与爱思唯尔在审稿人遴选、利益冲突管理、数据共享与编辑独立性方面的标准。
• The masthead and board roster are published on the journal page at ScienceDirect and updated as new members join or existing members step down编委名单在（ScienceDirect）期刊页公布，并随成员增减而更新。